Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
Top DNA sequencing company Illumina (NASDAQ: ILMN) has signed a pact with global pharmaceutical giant Roche (OTC: RHHBY) in the field of oncology, the Illumina's CEO Francis deSouza announced. On Monday, deSouza shared the news at the high-profile annual J.P. Morgan Healthcare Conferen...
Coherus BioSciences ( CHRS -2% ) inks an agreement Chinese biotech Innovent Biologics for U.S. and Canadian commercialization rights to the latter's biosimilar to Roche's ( OTCQX:RHHBY +0.2% ) cancer med Avastin (bevacizumab). More news on: Coherus BioSciences, Inc., Roche Holding AG...
Faced with pushback from multiple fronts over high drug prices, biopharmaceutical firms are experimenting with new ways to get paid for their priciest offerings, mostly biologics, in a report from the WSJ. More news on: Alnylam Pharmaceuticals, Inc., Sanofi, Novartis AG, Healthcare stock...
SEATTLE, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, globa...
It used to be that healthcare companies released news at the J.P. Morgan Healthcare Conference. In the last few years, the Friday before the conference became a news dump. Now, the whole week before the conference has become a news extravaganza. The conference is starting later in January t...
The midwest's largest pharmaceutical company, Eli Lilly (NYSE: LLY), recently made a big bet on a protein that nearly landed on a scrap heap just a couple of years ago. Today, Lilly announced its plans to acquire Dermira (NASDAQ: DERM) a commercial-stage biotechnology company d...
Investment Thesis With R&D expenses rising, the global pharma industry is increasingly relying on data analytics for speedier and cost-effective clinical trials. The new approach has the backing of the FDA, which recently approved new therapies based on the real-world data. The glob...
Merck's cancer immunotherapy finally hit a stumbling block in a pivotal study with lung cancer patients that caused the stock to slip 1.5% on Tuesday morning. It's more than a little surprising because Keytruda has been taking huge steps toward becoming the world's top-selling drug since M...
Illumina (NASDAQ: ILMN) is a giant in the field of DNA sequencing. Using its machines, biotech companies can design drugs to target specific cell receptors in the human body. Illumina's stock has been a monster for years; it's up 5,791% since the company's initial public offering i...
Results from a new study showed that end-of-year drug approvals by the FDA are linked to more hospitalizations, life-threatening events and deaths, a rate about twice as high as medicines approved earlier in the year. More news on: ProShares Trust - ProShares Ultra Nasdaq Biotechnology,...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Thursday, Argenx SE (NASDAQ:ARGX) shares are trading higher in reaction to Chugai Pharmaceutical Co Ltd’s disappointing g...
Wednesday, Roche Holding AG (OTC:RHHBY) entered into a definitive agreement with Lonza Group Ltd (OTC:LZAGF) (OTC:LZAGY). Under...
On Thursday, the FDA approved BeiGene Ltd’s (NASDAQ:BGNE) approved Tevimbra (tislelizumab-jsgr) as monotherapy for adult patients w...